PRIMARY STUDY
Chronic pain in Alzheimer's disease: Endocannabinoid system
Key Findings: This review summarizes how the endocannabinoid system (ECS) plays a crucial role in chronic pain, and how future studies may offer therapeutic targets in the ECS for chronic pain in Alzheimer's Disease.
Type of Study: Meta-analysis
Study Result: Positive
Research Location(s): United States
Year of Pub: 2023
Cannabinoids Studied: Tetrahydrocannabinol (THC), CP-x Synthetic Cannabinoids, WIN-x Synthetic Cannabinoids, Anandamide (AEA), Fatty Acid Amide Hydrolase (FAAH), 2-Arachidonoyl Glycerol (2-AG), Monoacylglycerol Lipase (MAGL), Endocannabinoid (unspecified)
Phytocannabinoid Source: Not Applicable
Receptors Studied: CB1, CB2, GPCR, CB1 antagonist, CB2 agonist
Citation: Blanton H, et al. Chronic pain in Alzheimer's disease: Endocannabinoid system. Exp Neurol. 2023; 360:114287. doi: 10.1016/j.expneurol.2022.114287
Authors: Blanton H, Reddy PH, Benamar K
